Dr. Jennifer Brown on the Role of FCR in CLL

Jennifer Brown MD, PhD
Published: Wednesday, Jul 13, 2016


Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses fludarabine, cyclophosphamide and rituximab (FCR) and other treatment options for young, fit patients with chronic lymphocytic leukemia (CLL).
 
FCR is the standard frontline therapy for young, fit patients with CLL, says Brown. The benefit of FCR over bendamustine and rituximab (BR) was further confirmed recently by three long-term follow-up trials with FCR. These trials demonstrated that a subset of patients remained progression-free at 12 years. Approximately 60% of patients with mutated IDH CLL will be basically cured with this treatment, says Brown.
 
However, patients with higher-risk unmated CLL do show continuous replace after 6 months of treatment with FCR. They have a median progression-free survival (PFS) of 5 years. Ibrutinib is approved in this setting, but for a young fit patient side effects should be considered.
 
SELECTED
LANGUAGE

Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses fludarabine, cyclophosphamide and rituximab (FCR) and other treatment options for young, fit patients with chronic lymphocytic leukemia (CLL).
 
FCR is the standard frontline therapy for young, fit patients with CLL, says Brown. The benefit of FCR over bendamustine and rituximab (BR) was further confirmed recently by three long-term follow-up trials with FCR. These trials demonstrated that a subset of patients remained progression-free at 12 years. Approximately 60% of patients with mutated IDH CLL will be basically cured with this treatment, says Brown.
 
However, patients with higher-risk unmated CLL do show continuous replace after 6 months of treatment with FCR. They have a median progression-free survival (PFS) of 5 years. Ibrutinib is approved in this setting, but for a young fit patient side effects should be considered.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x